Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Application of liquid biopsy-based targeted capture sequencing analysis to improve the precision treatment of non-small cell lung cancer by tyrosine kinase inhibitors.

BMJ open respiratory research - 1 Jan 2022

Zhang Lei, Coffin John, Formenti Kim, Chu Quincy, Izevbaye Iyare

Abstract excerpt

BACKGROUND: Targeted therapy of patients with non-small cell lung cancer (NSCLC) who harbour sensitising mutations by tyrosine kinase inhibitors (TKIs) has been found more effective than traditional chemotherapies. However, target genes status (eg, epidermal growth factor receptor (EGFR) TKIs sensitising and resistant mutations) need to be tested for choosing appropriate TKIs. This study is to investigate the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Non-Small-Cell Lung
Share to Drug Resistance, Neoplasm

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to ErbB Receptors

Share to Liquid Biopsy

Share to Lung Neoplasms

Share to Mutation

Share to Protein Kinase Inhibitors

Source

Open in PubMed Open full text

Identifiers

PMID: 35091437
DOI: 10.1136/bmjresp-2021-001154
PMCID: PMC8804681

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Application of liquid biopsy-based targeted capture sequencing analysis to improve the precision treatment of non-small cell lung cancer by tyrosine kinase inhibitors.PMID 35091437Read ↗

Detection of EGFR mutations using target capture sequencing in plasma of patients with non-small-cell lung cancerSemantic proximity Read ↗

An update on liquid biopsy analysis for diagnostic and monitoring applications in non-small cell lung cancer.Semantic proximity Read ↗

Enhanced Detection of Druggable Mutations in Non–Small Cell Lung Cancer Using Targeted Collection of Bronchial Washing Fluid Compared With Plasma and Tumor TissueSemantic proximity Read ↗

Use of capture-based next-generation sequencing to detect ALK fusion in plasma cell-free DNA of patients with non-small-cell lung cancerSemantic proximity Read ↗

The evolving paradigm of precision medicine in lung cancer.Semantic proximity Read ↗

Noninvasive genotyping and monitoring of anaplastic lymphoma kinase (ALK) rearranged non-small cell lung cancer by capture-based next-generation sequencing.Semantic proximity Read ↗

Efficacy of liquid biopsy for disease monitoring and early prediction of tumor progression in EGFR mutation-positive non-small cell lung cancer.Semantic proximity Read ↗

Next-generation sequencing of tissue and circulating tumor DNA: Resistance mechanisms to EGFR targeted therapy in a cohort of patients with advanced non-small cell lung cancerSemantic proximity Read ↗

Next-generation sequencing of tissue and circulating tumor DNA: Resistance mechanisms to EGFR targeted therapy in a cohort of patients with advanced non-small cell lung cancer.Semantic proximity Read ↗

A Prospective Study of Circulating Tumor DNA to Guide Matched Targeted Therapy in Lung CancersSemantic proximity Read ↗

Detection of plasma EGFR mutations for personalized treatment of lung cancer patients without pathologic diagnosis.Semantic proximity Read ↗

Comparison of cross-platform technologies for EGFR T790M testing in patients with non-small cell lung cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.